The dual blockade of MET and VEGFR2 signaling demonstrates pronounced inhibition on tumor growth and metastasis of hepatocellular carcinoma
Abstract Background The application of VEGF signaling inhibitors have been associated with more invasive or metastatic behavior of cancers including hepatocellular carcinoma (HCC). We explored the contribution of MET pathway to the enhanced HCC invasion and metastasis by VEGF signaling inhibition, a...
Main Authors: | Yu Zhang, Xiaomei Gao, Ying Zhu, Dhruba Kadel, Haoran Sun, Jing Chen, Qin Luo, Haoting Sun, Luyu Yang, Jing Yang, Yuanyuan Sheng, Yan Zheng, Kejin Zhu, Qiongzhu Dong, Lunxiu Qin |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-04-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13046-018-0750-2 |
Similar Items
-
Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016–Present)
by: Qian Zhang, et al.
Published: (2020-06-01) -
Pharmacophore screening, molecular docking, and MD simulations for identification of VEGFR-2 and c-Met potential dual inhibitors
by: Junmin Dong, et al.
Published: (2025-03-01) -
In Silico Analysis of Triamterene as a Potential Dual Inhibitor of VEGFR-2 and c-Met Receptors
by: Stuart Lutimba, et al.
Published: (2024-12-01) -
Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumors
by: Yu-Xiang Ma, et al.
Published: (2022-10-01) -
VEGFA, VEGFR1, VEGFR2 serum and cerebrospinal fluid concentration in patients with acute leukemia
by: E. I. Zakharko, et al.
Published: (2024-04-01)